A day after cutting the price range on its initial public offering, medical device company Amedica wound up pricing the IPO well under even the low end of its $8-$10 range, bringing in about $20.1 million from its $5.75-per-share offering of 3.5 million shares.
NASDAQ
Amedica lowers IPO price range, boosts shares on offer
Medical device company Amedica lowered the price range for its impending initial public offering, but said it would put more shares on offer.
Orthofix gets Nasdaq delisting warninga amid delayed earnings
Holaira raises $10M for lung device | Wall Street Beat
Medical device company Holaira said it drummed up $10 million, changed its name and moved its headquarters.
Formerly known as Innovative Pulmonary Solutions, Holaira said it plans to use the Series C round to develop its minimally invasive devices to treat obstructive lung disease. All of Holaira’s existing backers participated, namely Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures.
Medtronic closes strategic investment in LifeTech | Wall Street Beat
Medtronic (NYSE:MDT) said it’s closed a $66 million investment in Chinese medical device company LifeTech Scientific (HK:8122).
Wall Street shuts down for 2nd day | Wall Street Beat
The New York Stock Exchange was closed for a 2nd day today for the 1st time in 124 years, after Hurricane Sandy had its way with lower Manhattan yesterday. The storm also took out the NASDAQ exchange.
The Category I hurricane killed at least 108 people as is raged up the Eastern Seaboard from the Caribbean, 39 of them in the U.S.
The NYSE and NASDAQ said they plan to re-open tomorrow.
Greatbatch proposes to mostly exit Switzerland for Indiana, Mexico | Wall Street Beat
Greatbatch (NYSE:GB) said it wants to largely shutter a pair of plants in Switzerland and relocate their operations to Ft. Wayne, Ind., and Tijuana, Mexico.
HeartWare closes enrollment in destination therapy trial for heart pump | Wall Street Beat
HeartWare International (NSDQ:HTWR) completed enrollment in a 450-patient pivotal trial considering its ventricular assist system as a destination therapy for patients with advanced heart failure.
Report: J&J set for EU OK on Synthes buyout | Wall Street Beat
European Union regulators are poised to give the OK to Johnson & Johnson‘s (NYSE:JNJ) $21.3 billion acquisition of Swiss orthopedic giant Synthes, according to Reuters.
Standard & Poor’s downgrades Medtronic | Wall Street Beat
Standard & Poor’s Ratings Services downgraded Medtronic’s (NYSE:MDT) credit rating after the company reported declines for its bread-and-butter CRM and spine businesses – which together accounted for more than 50 percent of its total Q2 revenues.
CRDM revenues were up 1.6 percent to $1.27 billion for the quarter, but defibrillator sales slid 5.0 percent to $708 million.